Indicators
Indicators
Value
Direction
MACD(12,26,9)
0.024
Buy
RSI(14)
60.757
Neutral
STOCH(KDJ)(9,3,3)
75.145
Buy
ATR(14)
0.077
High Vlolatility
CCI(14)
168.866
Buy
Williams %R
13.083
Overbought
TRIX(12,20)
0.756
Sell
StochRSI(14)
100.000
Buy
SeaStar Medical Holding Corp
ICU0.848USD
-0.051-5.72%
Close 08/27, 16:00（ET）Quotes delayed by 15 min
14.70MMarket Cap
LossP/E TTM
TradingKey Stock Score
Financial Health
Valuation Dimension
Forecast
Momentum
Institutional Confidence
Risk Assessment
Peers
TradingKey Stock Score
Currency: USD Updated：2025-08-26Key Insights
Its valuation is considered undervalued,and institutional recognition is very high.Over the past 30 days, multiple analysts have rated the company as a Buy.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Score
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analysts' Target
Based on
1
analysts
Buy
Current Rating
2.000
Target Price
+124.95%
Upside Space
Disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Company Highlights
StrengthsRisks
SeaStar Medical Holding Corporation is a commercial-stage medical technology company. The Company is focused on developing extracorporeal therapies to reduce the consequences of hyperinflammation on vital organs. The Company's technologies rely on science to provide life-saving solutions to critically ill patients. The Company develops and commercializes cell-directed extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. The Company uses its Selective Cytopheretic Device (SCD) technology platform to clinically validate several acute organ injury indications, including kidneys and lungs. Its investigational SCD is an extracorporeal synthetic membrane device designed to integrate into existing continuous renal replacement therapy (CRRT) systems that are commonly installed in hospitals throughout the United States.
Growing
The company is in a growing phase, with the latest annual income totaling USD 135.00K.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 103.69.
Fairly Valued
The company’s latest is -0.48, at a medium 3-year percentile range.
Institutional Buying
The latest institutional holdings are 1.04M shares, increasing 33.78% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 57.50K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.94.
Financial Health
Currency: USD Updated：2025-08-26There is no financial score for this company; the Healthcare Services & Equipment industry's average is 7.15.
Score
Financials
Related Indicators
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
No Data
Quality of Earnings
Operational Efficiency
Growth Potential
Shareholder Returns
Valuation Dimension
Currency: USD Updated：2025-08-26The company’s current valuation score is 1.20, which is lower than the Healthcare Services & Equipment industry's average of 2.15. Its current P/E ratio is -0.48, which is -39.24% below the recent high of -0.29 and -4.79% above the recent low of -0.51.
Score
Valuation Dimension
P/E
P/B
P/S
P/CF
Industry Ranking 182/281
No Data
Forecast
Currency: USD Updated：2025-08-26The company’s current earnings forecast score is 8.00, which is higher than the Healthcare Services & Equipment industry's average of 7.66. The average price target for SeaStar Medical Holding Corp is 2.00, with a high of 2.00 and a low of 2.00.
Score
Support & Resistance
No Data
Analyst Rating
Based on
1
analysts
Buy
Current Rating
2.000
Target Price
+122.44%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
117
Total
7
Median
9
Average
Company name
Ratings
Analysts
SeaStar Medical Holding Corp
ICU
1
Medtronic PLC
MDT
35
Stryker Corp
SYK
33
Abbott Laboratories
ABT
31
Zimmer Biomet Holdings Inc
ZBH
30
Dexcom Inc
DXCM
28
1
2
3
...
24
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
No Data
Disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Momentum
Currency: USD Updated：2025-08-26The company’s current price momentum score is 1.91, which is lower than the Healthcare Services & Equipment industry's average of 7.39. Sideways: Currently, the stock price is trading between the resistance level at 1.05 and the support level at 0.64, making it suitable for range-bound swing trading.
Score
Support & Resistance
No Data
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
0.838
Buy
MA10
0.823
Buy
MA20
0.780
Buy
MA50
0.691
Buy
MA100
0.974
Sell
MA200
1.487
Sell
Institutional Confidence
Currency: USD Updated：2025-08-26The company’s current institutional recognition score is 3.00, which is lower than the Healthcare Services & Equipment industry's average of 7.19. The latest institutional shareholding proportion is 4.18%, representing a quarter-over-quarter decrease of 56.11%. The largest institutional shareholder is The Vanguard, holding a total of 57.50K shares, representing 0.21% of shares outstanding, with 86.53% decrease in holdings.
Score
Institutional Shareholding
No Data
Shareholder Activity
Name
Shares Held
Chg %
Neuman (John)
Geode Capital Management, L.L.C.
XTX Markets LLC
Schlorff (Eric)
Tyche Wealth Partners LLC
Chung (Kevin)
Raymond James Financial Services Advisors, Inc.
1
2
Risk Assessment
Currency: USD Updated：2025-08-26The company's beta value is -0.97. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.
Score
Beta vs S&P 500 index
-0.99
VaR
--
240-Day Maximum Drawdown
+94.04%
240-Day Volatility
+145.83%
Return
Best Daily Return
60 days
+47.62%
120 days
+47.62%
5 years
--
Worst Daily Return
60 days
-63.89%
120 days
-63.89%
5 years
--
Sharpe Ratio
60 days
+0.74
120 days
+0.03
5 years
--
Risk Assessment
Maximum Drawdown
240 days
+94.04%
3 years
+99.89%
5 years
--
Return-to-Drawdown Ratio
240 days
-0.88
3 years
-0.33
5 years
--
Skewness
240 days
-1.08
3 years
+0.90
5 years
--
Volatility
Realised Volatility
240 days
+145.83%
5 years
--
Standardised True Range
240 days
+20.60%
5 years
--
Downside Risk-Adjusted Return
120 days
+3.64%
240 days
+3.64%
Maximum Daily Upside Volatility
60 days
+223.58%
Maximum Daily Downside Volatility
60 days
+164.83%
Liquidity
Average Turnover Rate
60 days
+101.44%
120 days
+52.30%
5 years
--
Turnover Deviation
20 days
-94.47%
60 days
-73.21%
120 days
-86.19%
Peers
Currency: USD Updated：2025-08-26SeaStar Medical Holding Corp
ICU
2.46 /10
Score
Financial Health
Valuation Dimension
Forecast
Momentum
Institutional Confidence
Risk Assessment
Insulet Corp
PODD
7.26 /10
Score
Financial Health
Valuation Dimension
Forecast
Momentum
Institutional Confidence
Risk Assessment
Merit Medical Systems Inc
MMSI
7.23 /10
Score
Financial Health
Valuation Dimension
Forecast
Momentum
Institutional Confidence
Risk Assessment
Brightspring Health Services Inc
BTSG
7.19 /10
Score
Financial Health
Valuation Dimension
Forecast
Momentum
Institutional Confidence
Risk Assessment
Tenet Healthcare Corp
THC
7.14 /10
Score
Financial Health
Valuation Dimension
Forecast
Momentum
Institutional Confidence
Risk Assessment
Thermo Fisher Scientific Inc
TMO
7.14 /10
Score
Financial Health
Valuation Dimension
Forecast
Momentum
Institutional Confidence
Risk Assessment
View more
The Stock Score data is powered by TradingKey and updated daily. Rating data is sourced from LESG. Please use the data with caution for reference purposes only.
